A Phase II, Open-Label, Randomized, Controlled Study to Evaluate Efficacy and Safety of Vactosertib and Imatinib Combination in Patients With Advanced Desmoid Tumor (Aggressive Fibromatosis) Compared With Imatinib Monotherapy
Latest Information Update: 11 Dec 2024
At a glance
- Drugs Imatinib (Primary) ; Vactosertib (Primary)
- Indications Fibroma
- Focus Therapeutic Use
- Acronyms MP-VAC-206
- Sponsors MedPacto
Most Recent Events
- 09 Dec 2024 Status changed from recruiting to withdrawn prior to enrolment.
- 29 Jan 2024 New trial record